Brief: Poxel Initiates Study As Part Of Clinical Program For PXL770

Poxel SA

05/08/2019 07:49

Aug 5 (Reuters) - POXEL SA  POXEL.PA :
    * POXEL INITIATES PHARMACOKINETIC (PK)/ PHARMACODYNAMIC (PD)
STUDY
AS PART OF THE PHASE 2A CLINICAL PROGRAM FOR PXL770, A DIRECT
AMPK ACTIVATOR FOR THE TREATMENT OF NASH
    * DATA RESULTS FROM PK/PD STUDY ARE ANTICIPATED IN Q4 2019,
PHASE
2A EFFICACY AND SAFETY RESULTS ARE ANTICIPATED IN Q2 2020

Source text for Eikon:  ID:nBw7xHFQ1a 
Further company coverage:  POXEL.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; 48 58 772 0920;))